The FDA has tied sodium-glucose cotransporter-2 inhibitors to 55 cases of a life-threatening form of gangrene in the past six years, according to a May 7 report in the Annals of Internal Medicine.

The prevalence of heart failure (HF) in the U.S. is increasing hand-in-hand with rising rates of diabetes and obesity, according to a recent analysis, and HF-related CVD death rates have followed suit—most notably in younger adults.

Heart disease is now the leading cause of maternal deaths in the U.S., the American College of Obstetricians and Gynecologists (ACOG) reported in early May, prompting the organization to publish a comprehensive guide on pregnancy and CVD.

Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.

Researchers at the University of Georgia have uncovered 27 new metabolites associated with arterial stiffness, according to work published in the American Journal of Hypertension.

The FDA issued an alert May 7 warning patients with certain implanted Medtronic pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) and their care teams to check for premature battery depletion in their devices after defects resulted in three reports and one patient death.

Individuals with heart failure with preserved ejection fraction (HFpEF) and atrioventricular block might benefit more from cardiac resynchronization therapy (CRT) than conventional right ventricular (RV) pacing, according to research published in JACC: Heart Failure.

Cardiac abnormalities stemming from preterm birth can be corrected with a three-and-a-half-month exercise program in patients’ teens and twenties, according to a drug-free trial of Canadian adults.

Drinking water contaminated with inorganic arsenic could increase young adults’ risk of CVD by thickening the heart’s left ventricular (LV) wall and triggering hypertrophy, researchers reported in Circulation: Cardiovascular Imaging May 7.

A new biotech company out of Massachusetts is levering human genetics and genome editing to “turn the tide” of coronary artery disease (CAD), experimenting with CRISPR to stop CAD from ever developing in at-risk individuals.

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.